-
Efficient technology
Anticipates risks of tumor escape
Answers huge unmet need in solid tumors -
Derisked approach
2nd generation of innovative immuno-oncology
FDA Pre-IND passed
Top scientific leaders on board
GMP manufacturing ready -
Limitless potential
IP by design-platform strategy
Tailored first-in-class drugs design
Dynamic immuno-oncology market
Key milestones validated
-
Regulatory
- mCRC preclinical package endorsed by FDA & FAMHP (EMA)
- STC 1010 FDA pre-IND and 2 SA with EU FAMHP passed
-
First In Human
- Phase I/II 1L mCRC study synopsis validated
-
Manufacturing
- Product - GLP, Drugs subsances - GMP
- Gap Analysis
- Pre scale-up & Tech transfer - GMP, experienced CDMO
-
IP
- STC platform design - Granted in Key countries
- STC-1010 Product - Published
-
Team
- Highly skilled executives & internationally renowed KOLs
Competitive advantages
STC Technology overpassing current challenges in the field of immuno oncology
Brenus Pharma stimulated tumor cell line (STC)
The 2nd generation of an impactful haptenized immunotherapy
- 1st Technology to cover 3 types of targets in one solution. Allowing presentation of +100 qualitative antigens, anticipating patient relapse.
- No HLA restriction
- Haptenization overpassing lack of immunogenicity with maintened safety
- GMP manufacturing process ready
With the support of
With the support of
-
DEEPTECH LABEL
by BPI (French Public Investment Bank) -
EUROSTARS - ALLOGENIX project
Brenus Pharma x InSphero AG
Nov 2022 - Nov 2025 -
-
-
Our awards
-
MATWIN 2021 award -
Finalist 2022 -
BIOLABS MASTERCLASS
Boston 2022 -
2022 PRIX GALIEN USA AWARD NOMINEE
"Best startup in the Pharmaceutical or Biotech industry" -
ENRICH IN USA 2022 award